NCT06492226View on ClinicalTrials.gov

Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

October 23, 2024

Study Completion Date

November 6, 2024

Conditions
Healthy Participants
Interventions
DRUG

NKF-INS(A)

Single subcutaneous dose of 0.3 U/kg administration over three treatment periods

DRUG

EU-NovoRapid®

Single subcutaneous dose of 0.3 U/kg administration over three treatment periods

DRUG

US-NovoLog®

Single subcutaneous dose of 0.3 U/kg administration over three treatment periods

Trial Locations (1)

9301

Xentria Investigative Site, Bloemfontein

All Listed Sponsors
lead

Xentria, Inc.

INDUSTRY

NCT06492226 - Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid® | Biotech Hunter | Biotech Hunter